Exabis Library

During the past decades, human diet has evolved towards higher intakes of processed and ultraprocessed food. We have investigated the association between these food groups and the risk of inflammatory bowel disease (IBD) in the European Prospective Investigation into Cancer and Nutrition.

413 590 participants from 8 European countries were included. Dietary data were collected at baseline from validated food frequency questionnaires. All EPIC food items were expressed as g/day and categorized according to the NOVA classification: “group 1—unprocessed or minimally processed foods”; “group 2—processed culinary ingredients”; “group 3—processed foods”; and “group 4—ultra-processed foods (UPFs)”. Because the EPIC dietary questionnaires were conceived before the NOVA classification, the food items were retrospectively categorized into this classification. Some food items collected in the EPIC questionnaires were difficult to categorize into group 3 or 4. We therefore merged them into a single category. We tested three scenarios for the estimation of the dietary content of this merged category: lower, middle and upper contents of groups 3 + 4. The association between the proportion of each NOVA group in the diet and IBD were estimated using Cox proportional hazard models to obtain Hazards Ratios (HRs) and 95% confidence intervals. We adjusted the HR for smoking status, educational level, physical activity, BMI, alcohol consumption and energy intake and stratified by centre, age at baseline (1-y interval), and sex.

After a mean follow-up of 16 years, 179 Crohn's disease (CD) and 431 ulcerative colitis (UC) cases were identified. NOVA group 1 was negatively associated with CD risk (adjusted HR for the fourth vs. the first quartile = 0.58; 95% CI = 0.35-0.95; P-trend = 0.03). Within group 1, fruit intake was the only food item to be negatively associated with the risk of IBD (adjusted HR for the fourth vs. the first quartile = 0.42; 95% CI = 0.24-0.73; P-trend = 0.003). We found numerical associations between group 3+4 and the risk of CD with the middle or upper scenarios (adjusted HRs for the fourth vs. the first quartile = 1.50; 95% CI = 0.92-2.46; P-trend = 0.12 and 1.41; 95% CI = 0.88-2.27; P-trend = 0.09 respectively). There was no association between any category of the NOVA classification and UC risk.

In the EPIC cohort, consumption of non-processed food was associated with a lower risk of CD while consumptions of processed or ultra-processed food were numerically associated with increased risk of CD. We found no association with UC.

1) To use IBD prognostic factors to improve management decisions
2) To review why intervene early if poor prognosis
3) To understand the challenges in biomarkers development
4) To learn which promisig biomarkers have been validated for clinical implementation or are undergoing validation

Sarit Hoffman describes her work measuring faecal protease activity in patients with pouchitis, and linking this to specific bacteria and downstream effects on epithelial barrier function mediated via PAR2.

Psychological difficulties are common in people with IBD. In this session I will present the biopsychosocial model of health and discuss how it is involved in the development, maintenance and treatment of IBD. I will discuss how the MDT can support with psychosocial components and why it’s important and briefly discuss the evidence around psychological therapy in IBD.

1. To understand the impact of IBD on the daily lives of patients
2. To review the possible psychological and social issues affecting the quality of life in IBD patients
3. To emphasize the role of the IBD nurse in patient support

Educational objectives:
1. To understand the impact of IBD on individual's life e.g. education, employment, relationship, body image, self-esteem
2. To understand the impact of IBD on psychosocial well-being of the individual living with IBD e.g. stress, anxiety, depression, fatigue, food related quality of life, sexuality
3. To review the evidence on psychological well-being of people living with IBD
4. To have an overview of the assessment tools and the support systems available to patients